http://tickerreport.com/banking-finance/474507/roth-capital-initiates-coverage-on-mast-therapeutics-anx/?utm_source=ADVFN&utm_medium=banner&utm_cam...
Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial Sub-study will investigate effects of MST-188 on tissue oxygenation in sickle...
Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease MST-188 decreased a marker of inflammation and red blood cell...
Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc. - All-stock transaction - Conference call to discuss pending...
Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10 PR Newswire SAN DIEGO, Sept. 3, 2013...
ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX" PR Newswire SAN DIEGO, March 11, 2013...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX" Name and ticker symbol...
Adventrx To Develop ANX-188 For Complications Of Arterial Disease - Seeking orphan drug designation in acute limb ischemia (ALI) - Phase 2...
ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications - Platform includes over 100 pharmacology studies, 15 clinical studies...
ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4 PR Newswire SAN DIEGO, Feb. 25, 2013 SAN DIEGO, Feb...
ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188 PR Newswire SAN DIEGO, Feb. 11, 2013 SAN DIEGO, Feb. 11, 2013 /PRNewswire/...
ADVENTRX To Present At The 15th Annual BIO CEO & Investor Conference On February 12 /* Style Definitions */ span.prnews_span { font-size:8p...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads